By Josh White
Date: Wednesday 20 Aug 2025
(Sharecast News) - Hutchmed China said in an update on Wednesday that it has completed patient enrollment in its phase three 'Sanovo' trial in China testing a combination of 'Orpathys', or savolitinib, and 'Tagrisso', or osimertinib, as a first-line therapy for certain non-small cell lung cancer patients.
Directorate Change | 26-Aug-2025 | 07:00 | RNS |
2025 Interim Results | 07-Aug-2025 | 12:00 | RNS |
HUTCHMED to Announce 2025 Half-Year Results | 03-Jul-2025 | 09:30 | RNS |
Update on Joint Corporate Brokers in London | 02-Jul-2025 | 10:00 | RNS |
China Approval based on Phase III SACHI Trial | 30-Jun-2025 | 09:30 | RNS |
Chinese medicine firm employs Cambridge Universi... | 23-Dec-2009 | Guardian |
Joint venture offers food for growth | 09-Oct-2009 | The Scotsman |
Chi-Med unveils maiden profit | 31-Jul-2009 | The Scotsman |
Chi-Med happy with drug tests | 14-Jul-2009 | The Scotsman |
'Watershed' year depends on US drugs trial says ... | 17-Mar-2009 | The Scotsman |
Questor: Hutchison China Meditech | 03-Jul-2007 | Telegraph |
The Week Ahead: Wolseley investors seek calm ami... | 19-Mar-2007 | The Independent |
The Investment Column: Hutchison China MediTech | 21-Nov-2006 | The Independent |
Shares That Sound Good | 02-Jun-2006 | Motley Fool UK |
No recent information was found.
Currency | UK Pounds |
Share Price | 218.00p |
Change Today | -0.50p |
% Change | -0.23 % |
52 Week High | 325.00p |
52 Week Low | 189.00p |
Volume | 11,703 |
Shares Issued | 872.11m |
Market Cap | £1,901.20m |
RiskGrade | 226 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
15:16 | 1 @ 226.37p |
14:41 | 100 @ 218.00p |
13:45 | 1,100 @ 219.78p |
12:34 | 8 @ 218.00p |
12:34 | 1,605 @ 218.00p |
You are here: research